Newron to resubmit troubled Parkinson’s drug to FDA; abuse risks cleared

FDA grants fast-track status to Morphochem’s antibiotic ahead of start of PhII

Merck faces FDA delay for C. diff antibody amid trial data concerns

Manufacturing issues thwart FDA approval for Valeant eye drug

China to pip U.S. researchers to the post on first CRISPR trial

Vasorum gets FDA green light for its vascular closure device aimed at arterial punctures

Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B

Valeant wins FDA oral Relistor approval and $1B sales potential

UPDATED: FDA rejects Novartis’ biosim app for Amgen blockbuster

AstraZeneca wants to advance lung cancer drug after hitting PhIII target